What are the phases of a clinical trial?

Clinical trials progress through Phase 1 (safety testing in 20-100 volunteers), Phase 2 (efficacy testing in 100-500 patients), and Phase 3 (confirmatory testing in 1,000-5,000+ patients). After successful Phase 3, the company submits an NDA or BLA to the FDA for approval.

What is the success rate for clinical trials?

Overall, only about 10% of drugs that enter Phase 1 clinical trials eventually receive FDA approval. Phase 1 has a 65% success rate, Phase 2 has a 30% success rate (the highest attrition phase), Phase 3 has a 58% success rate, and NDA/BLA approval is about 85%.

How long does a clinical trial take?

The full clinical development process typically takes 6-10 years. Phase 1 trials last 6-12 months, Phase 2 trials take 1-2 years, Phase 3 trials take 2-4 years, and FDA review adds another 6-12 months. Total cost from preclinical through approval can exceed $1 billion.

What is the difference between Phase 2a and Phase 2b?

Phase 2a is a smaller proof-of-concept study (50-100 patients) that tests whether the drug shows any activity. Phase 2b is a larger dose-ranging study (100-300 patients) that identifies the optimal dose for Phase 3. Phase 2 is the highest-risk phase with only a 30% success rate.

What is an adaptive clinical trial?

An adaptive clinical trial allows modifications to the trial design based on interim data analysis. This includes seamless Phase 2/3 designs, platform trials that test multiple treatments, basket trials (one drug in multiple cancers), and umbrella trials (one cancer with multiple drugs). Adaptive designs can be faster and more efficient than traditional designs.

Back to Learn

Clinical Trial Phases Explained

Clinical

Clinical trials are the backbone of drug development. Understanding each phase helps investors assess pipeline value and catalyst significance.

Clinical Development Overview

Drug development follows a structured pathway:

Discovery → Preclinical → Phase 1 → Phase 2 → Phase 3 → NDA/BLA → Approval
           (Animals)      (Safety)  (Efficacy) (Confirm)  (Review)

Development Timeline

Phase	Duration	Patients	Cost
Preclinical	1-3 years	Animals	$10-50M
Phase 1	6-12 months	20-100	$20-50M
Phase 2	1-2 years	100-500	$50-100M
Phase 3	2-4 years	1,000-5,000+	$100-500M
FDA Review	6-12 months	-	$2-3M

Preclinical Studies

Before human trials begin, drugs must demonstrate safety in laboratory and animal studies.

Key Preclinical Work

In vitro studies - Cell cultures, biochemical assays
In vivo studies - Animal models (mice, rats, primates)
Toxicology - Organ toxicity, carcinogenicity
Pharmacokinetics - Absorption, distribution, metabolism, excretion (ADME)
Pharmacodynamics - Mechanism of action, dose-response

IND Filing

An Investigational New Drug (IND) application must be submitted to FDA before human trials:

Preclinical data summary
Manufacturing information
Clinical trial protocol
Investigator qualifications

Pro Tip: Strong preclinical data, especially in relevant animal models, increases likelihood of clinical success.

Phase 1 Trials

Primary Objectives

Safety - Maximum tolerated dose (MTD)
Pharmacokinetics - How the drug is processed
Pharmacodynamics - How the drug works

Study Design

Characteristic	Typical Parameters
Participants	20-100 healthy volunteers
Duration	Several months
Design	Open-label, dose escalation
Endpoints	Safety, tolerability, PK/PD

Dose Escalation

Phase 1 typically uses a 3+3 design:

Start with 3 patients at lowest dose
If no toxicity, escalate to next dose
If toxicity, expand cohort to 6 patients
Continue until MTD is reached

Oncology Exception

In oncology, Phase 1 often enrolls cancer patients (not healthy volunteers) because:

Chemotherapy too toxic for healthy people
Patients may benefit even at early stages
Ethical considerations

Success Rate: ~65% of drugs successfully complete Phase 1 trials.

Phase 2 Trials

Primary Objectives

Efficacy - Does the drug work?
Optimal dosing - Best dose for Phase 3
Safety - Longer-term adverse events

Study Types

Phase 2a (Proof of Concept)

Small study (~50-100 patients)
Single-arm or small controlled trial
Tests if drug shows any activity

Phase 2b (Dose-Ranging)

Larger study (~100-300 patients)
Multiple dose arms
Identifies optimal dose for Phase 3

Study Design

Characteristic	Typical Parameters
Participants	100-500 patients with disease
Duration	1-2 years
Design	Randomized, controlled (often)
Endpoints	Efficacy signals, safety

Endpoints

Type	Definition	Examples
Primary	Main efficacy measure	Response rate, symptom reduction
Secondary	Supporting measures	Duration of response, QoL
Exploratory	Hypothesis-generating	Biomarkers, subgroups

Success Rate: Only ~30% of drugs successfully complete Phase 2 trials. This is the highest attrition phase.

Phase 3 Trials

Primary Objectives

Confirm efficacy - Definitive proof drug works
Characterize safety - Full adverse event profile
Support approval - Data for NDA/BLA

Study Design

Characteristic	Typical Parameters
Participants	1,000-5,000+ patients
Duration	2-4 years
Design	Randomized, double-blind, controlled
Endpoints	Clinical outcomes (OS, PFS, etc.)

Pivotal Trial Requirements

Randomized - Patients assigned by chance
Controlled - Comparison to placebo or active comparator
Blinded - Neither patient nor investigator knows assignment
Adequate powered - Sufficient sample size for statistical significance
Multi-center - Multiple sites for generalizability

Common Endpoints by Therapeutic Area

Area	Primary Endpoints
Oncology	Overall Survival (OS), Progression-Free Survival (PFS)
Cardiovascular	MACE (Major Adverse Cardiac Events)
CNS/Psychiatry	Symptom scales (HAM-D, PANSS)
Infectious Disease	Viral load, clinical cure
Autoimmune	ACR response, symptom remission

Success Rate: ~58% of drugs successfully complete Phase 3 trials. Phase 3 failure is often catastrophic for biotech stocks.

Success Rates by Phase

Based on BIO Industry Analysis 2024 data:

Transition	Success Rate
Phase 1 → Phase 2	65%
Phase 2 → Phase 3	30%
Phase 3 → NDA/BLA	58%
NDA/BLA → Approval	85%
Overall (Phase 1 → Approval)	~10%

Success by Therapeutic Area

Area	Phase 1-Approval LOA
Hematology	26%
Infectious Disease	20%
Ophthalmology	17%
Oncology	8%
CNS/Neurology	6%
Cardiovascular	7%

Reading Clinical Trial Results

Statistical Terms

Term	Definition
p-value	Probability result is due to chance (below 0.05 = significant)
Confidence Interval	Range likely to contain true effect
Hazard Ratio	Relative risk of event (HR below 1 = benefit)
NNT	Number needed to treat for one benefit

Red Flags in Trial Results

Missed primary endpoint
Narrow confidence intervals crossing 1.0
Post-hoc subgroup analyses
High dropout rates
Changed primary endpoint mid-trial

Green Flags

Met primary and secondary endpoints
Consistent effect across subgroups
Clean safety profile
Large effect size
Robust p-value (p below 0.001)

Adaptive and Novel Trial Designs

Adaptive Designs

Seamless Phase 2/3 - Continuous enrollment
Platform trials - Test multiple treatments
Basket trials - One drug, multiple cancers
Umbrella trials - One cancer, multiple drugs

Accelerated Programs

Accelerated Approval - Based on surrogate endpoints
Breakthrough Therapy - Intensive FDA guidance
RMAT - Regenerative medicine designation

Summary

Understanding clinical trials helps investors assess:

Phase 1 = Safety first, 65% success rate
Phase 2 = Proof of concept, 30% success rate (highest risk)
Phase 3 = Confirmatory, 58% success rate
Overall LOA = ~10% from Phase 1 to approval
Therapeutic area significantly impacts success rates

← Previous: NDA vs BLA

Next: FDA Designations →